Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (NCT06578247)

🧪 Interventions in This Study

• Quizartinib (DRUG)
• Placebo (DRUG)
• Chemotherapy (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (284 Sites)

Showing the first 25 of 284 sites.

• City of Hope Phoenix — Goodyear, Arizona
• Mayo Clinic - Phoenix — Phoenix, Arizona
• University of Arizona Cancer Center — Tucson, Arizona
• David Geffen School of Medicine — Los Angeles, California
• University of California Davis Health System — Sacramento, California
• Ucsf Helen Diller Family Comprehensive Cancer Center — San Francisco, California
• Stanford University School of Medicine- Parent — Stanford, California
• Colorado Blood Cancer Institute — Denver, Colorado
• Yale University — New Haven, Connecticut
• Sibley Memorial Hospital — Washington D.C., District of Columbia
• Mayo Clinic Hospital — Jacksonville, Florida
• Florida Hospital Cancer Institute - Kissimmee — Kissimmee, Florida
• Tampa General Hospital — Tampa, Florida
• Moffitt Cancer Center — Tampa, Florida
• Winship Cancer Institute of Emory University — Atlanta, Georgia
• Augusta University — Augusta, Georgia
• Robert H Lurie Comprehensive Cancer Center Northwestern University — Chicago, Illinois
• University of Illinois Hospital & Health Sciences System — Chicago, Illinois
• The University of Chicago Medical Center — Chicago, Illinois
• University of Kentucky — Lexington, Kentucky
• Ochsner Medical Center - New Orleans — New Orleans, Louisiana
• Johns Hopkins Hospital — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• University of Michigan Comprehensive Cancer Center Michigan Medicine — Ann Arbor, Michigan
• University of Minnesota Medical School - Twin Cities Campus — Minneapolis, Minnesota

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Leukemia

• Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia — San Diego, California
• AZD6738 for Patients With Progressive MDS or CMML — Boston, Massachusetts
• Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies — Philadelphia, Pennsylvania
• Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 — New York, New York
• Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL — Chicago, Illinois
• Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors — Memphis, Tennessee

Explore by condition: All Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.